Topic

Payers

1
Jul
2019

Has the Time Come for a US NICE?

There is growing discontent among many healthcare stakeholders with the Institute for Clinical and Evidence Review known as ICER, something which may not surprise many TR readers. Recently, I had the opportunity to moderate a panel on value-based agreements for the CBI/EBD Group Rare Disease Innovation & Partnering Summit in Boston. Among the topics that the panel discussed was the...
Read More
3
Jan
2019

Medicare’s CAR (-T) Wreck

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.